In trading on Wednesday, drugs shares were relative laggards, down on the day by about 1.9%. Helping drag down the group were shares of Flamel Technologies (FLML), down about 11% and shares of Stemline Therapeutics (STML) down about 8.8% on the day.
NEW YORK (TheStreet) -- The shares of Flamel Technologies
are rallying after two other companies, Jazz Pharmaceuticals
and Concert Pharmaceuticals
, decided not to continue development of their JZP-386 drug at this time. JZP-386 is a...
Flamel Technologies SA (NASDAQ: FLML) shares dipped 9.16% to $17.15 after the company announced the departure of Senior Vice President of Business and Corporate Development, Steve Lisi and reaffirmed FY15 product revenue forecast of $170 to $185...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.